RxDoctor Payments Data

Ahtaram Khan, MD

Family Medicine · Plano, TXNPI 1336258003

Payments from drug & device makers

$252,886in general payments, 2019–2025

Across 152 payments — averaging $1663.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$116K
  • Novartis$56K
  • AstraZeneca$46K
  • Amgen$23K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$12K
  • Novo Nordisk$286
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,055100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$252,886 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$56,128
Medicare patients
132
Services billed
572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide94$116,201
FarxigaDapagliflozin Propanediol36$39,515
TrulicityDulaglutide17$32,087
JanuviaSitagliptin Phosphate25$28,078
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$27,659
VemlidyTenofovir Alafenamide13$21,750
XareltoRivaroxaban21$21,142
JardianceEmpagliflozin20$20,682
MyrbetriqMirabegron18$12,937
Breo ElliptaFluticasone/Vilanterol24$10,437
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$9,036
Albuterol Sulfate HfaAlbuterol Sulfate81$2,984
Gabapentin131$2,606
Atorvastatin Calcium332$1,975
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,827

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$286$116,20194 claims
AstraZenecaFarxiga$45,573$39,51536 claims
GSKTrelegy Ellipta, Breo Ellipta$204$38,09645 claims
Lilly USA, LLCTrulicity$176$32,08717 claims
MerckJanuvia$100$28,07825 claims
Astellas Pharma US IncMyrbetriq$22$12,93718 claims
AbbVieSynthroid$28$1,17420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →